查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1930145

全球 GLP-2 類似物市場：市場規模、佔有率、成長率、產業分析、依類型、應用和地區劃分的分析以及未來預測（2026-2034 年）

GLP-2 Analogs Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 150 Pages | 商品交期: 請詢問到貨日

價格

GLP-2 類似物市場成長因子

由於胃腸道疾病（尤其是短腸症候群 (SBS)）的盛行率不斷上升，全球 GLP-2 類似物市場正經歷穩定成長。 GLP-2 類似物（胰高血糖素樣勝肽-2 類似物）是模擬天然 GLP-2 荷爾蒙作用的治療藥物，GLP-2 荷爾蒙在腸道生長、營養吸收和腸道完整性方面發揮重要作用。 這些藥物主要用於因腸道功能障礙而依賴腸外營養和補液的短腸症候群（SBS）患者。

根據這份報告，全球GLP-2類似物市場預計在2025年達到12億美元。預計該市場將在2026年增長至18.3億美元，並在2034年達到26.5億美元，在預測期（2026-2034年）內複合年增長率（CAGR）為6.08%。北美地區在全球市場中佔領先地位，預計到2025年將佔77.11%的市場佔有率，這得益於其先進的醫療基礎設施、創新療法的廣泛應用以及積極的臨床研究活動。 市場驅動因素 GLP-2類似物市場的主要驅動因素是全球短腸症候群（SBS）盛行率的不斷上升。短腸症候群 (SBS) 通常由大型胃腸道手術、先天性異常、克隆氏症以及其他導致腸道長度縮短或營養吸收不良的疾病引起。診斷能力的提高和腸道功能障礙患者生存率的提升，擴大了可治療的患者群體，直接增加了對 GLP-2 類似物療法的需求。

此外，腸道修復療法的臨床接受度不斷提高，以及 GLP-2 類似物已被證實能夠減少患者對全腸外營養 (TPN) 的依賴，進一步推動了市場成長。這些療法透過改善腸道吸收和減少與 TPN 相關的長期併發症，顯著提高了患者的生活品質。

市場限制因子

儘管 GLP-2 類似物療法具有臨床益處，但高昂的治療成本仍然是限制市場成長的主要因素。 GLP-2 類似物療法需要複雜的生產流程和大量的研發投入。 此外，這些療法通常需要每日或長期給藥，導致患者和醫療保健系統全年承受沉重的經濟負擔。成本限制阻礙了其廣泛應用，尤其是在發展中地區和價格敏感地區，減緩了整體市場擴張。

市場機會

長效GLP-2類似物的開發為市場帶來了強勁的成長機會。製藥公司正致力於研發每週一次的製劑，以提高患者的依從性並減少每日註射帶來的不便。諸如格雷帕魯肽和阿普拉魯肽等候選藥物旨在提供持續的治療效果，同時減少給藥頻率，預計這將對市場成長產生積極影響。

此外，製劑穩定性和藥物傳遞技術的創新有望提高治療效果，從而擴大GLP-2類似物的未來臨床應用範圍。

市場挑戰

GLP-2類似物市場面臨與生物製劑嚴格的監管要求相關的挑戰。 監管機構要求進行廣泛的臨床試驗，以確保藥物的長期安全性和有效性，特別關注胃腸道疾病等不良反應和其他潛在風險。這些監管障礙會增加研發成本、延長審批時間，並可能延遲新產品上市，進而抑制市場成長。

市場趨勢

影響市場發展的關鍵趨勢之一是，在短腸症候群 (SBS) 的治療中，治療方案正從全腸外營養轉向基於 GLP-2 的藥物。 GLP-2 類似物透過改善腸道功能和減少對侵入性營養支持的依賴，提供了更具針對性、更符合生理的治療方法。

另一個重要趨勢是臨床適應症的擴展，不再侷限於 SBS（短腸症候群）。目前的研究正在評估 GLP-2 類似物在克隆氏症、潰瘍性結腸炎、化療引起的腸道疾病和類固醇抗藥性胃腸道移植物抗宿主疾病的潛在應用，這有望拓展未來的市場機會。

市場區隔分析

依藥物類型劃分，市場分為特度格魯肽和其他藥物。特度格魯肽憑藉其已證實的安全性、明確的臨床療效以及獲批用於治療短腸綜合徵（SBS）的監管審批，佔市場主導地位。其他藥物（包括正在研發的長效類似物）預計在預測期內將穩定成長。

依給藥途徑劃分，市場分為腸外給藥及口服給藥。腸外給藥佔最大佔有率，因為大多數已核准的GLP-2類似物都是用於治療腸道功能障礙患者的注射療法。然而，由於患者依從性高以及口服勝肽遞送系統的進步，口服給藥也日益受到關注。

依分銷管道劃分，由於線上和線下藥局的便利性和可及性提高，它們佔了較大的市場佔有率。 同時，由於住院患者數量龐大，醫院藥局繼續發揮重要作用。

區域展望

北美地區引領全球GLP-2類似物市場，2025年市場規模達12.3億美元，預計2026年將成長至14.3億美元。先進療法的高普及率、完善的醫保體係以及積極的研發活動支撐了該地區的市場主導地位。歐洲由於短腸症候群（SBS）盛行率的上升和高昂的醫療保健支出，佔了相當大的市場佔有率。亞太地區預計在預測期內將實現顯著成長，這主要得益於臨床研究的拓展以及政府對罕見疾病的扶持政策。拉丁美洲以及中東和非洲地區預計將保持穩定成長，這主要得益於人們對先進療法的認識不斷提高以及獲得這些療法的途徑更加便捷。

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第四章：關鍵考慮因素

  • 主要國家短腸症候群盛行率（2025 年）
  • 主要公司產品線分析
  • 主要公司新產品發布
  • 關鍵產業趨勢：併購、業務合作等
  • 主要國家監管和報銷狀況區域

第五章 全球 GLP-2 類似物市場分析：洞察與預測 (2021-2034)

  • 市場分析、洞察與預測：依藥物分類
    • 特度格魯肽
    • 其他
  • 市場分析、洞察與預測：依給藥途徑分類
    • 口服
    • 腸外給藥
  • 市場分析、洞察與預測：依銷售管道分類
    • 醫院藥房
    • 線上及零售藥房
  • 市場分析、洞察與預測：依地區分類
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第六章 北美 GLP-2模擬市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 美國
    • 加拿大

第七章：歐洲 GLP-2 模擬市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 斯堪的納維亞
    • 歐洲其他地區

第八章：亞太地區 GLP-2 模擬市場分析：洞察與預測（2021-2034）

  • 依國家/地區
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 東南亞
    • 亞太其他地區

第九章：拉丁美洲 GLP-2 類似物市場分析：洞察與預測 (2021-2034)

  • 依國家劃分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區

第十章：中東與非洲 GLP-2 類似物市場分析：洞察與預測 (2021-2034)

  • 依國家劃分
    • 海灣合作委員會 (GCC) 國家
    • 南非
    • 中東和非洲其他地區

章節11 競爭分析

  • 全球市佔率分析（2025 年）
  • 公司簡介
    • Nestle
    • Takeda Pharmaceutical Company Limited
    • OxThera
    • Zealand Pharma
    • Ironwood
    • Hanmi Pharm Co., Ltd.
    • Jaguar Health
    • Merck KGaA
    • EnteraBio Ltd.
Product Code: FBI113558

Growth Factors of GLP-2 analogs Market

The global GLP-2 analogs market is experiencing steady growth due to the increasing prevalence of gastrointestinal disorders, particularly short bowel syndrome (SBS). GLP-2 analogs (glucagon-like peptide-2 analogs) are therapeutic agents that mimic the action of the naturally occurring GLP-2 hormone, which plays a crucial role in intestinal growth, nutrient absorption, and gut integrity. These drugs are primarily used in patients with SBS who depend on intravenous nutrition and fluids due to intestinal failure.

According to the report, the global GLP-2 analogs market was valued at USD 1.20 billion in 2025. The market is projected to grow to USD 1.83 billion in 2026 and further reach USD 2.65 billion by 2034, registering a CAGR of 6.08% during the forecast period (2026-2034). North America dominated the global market in 2025 with a 77.11% share, supported by advanced healthcare infrastructure, high adoption of innovative therapies, and strong clinical research activity.

Market Drivers

The primary driver of the GLP-2 analogs market is the rising global prevalence of short bowel syndrome. SBS commonly occurs due to extensive gastrointestinal surgeries, congenital defects, Crohn's disease, or other conditions resulting in reduced intestinal length and impaired nutrient absorption. Improved diagnostic capabilities and higher survival rates among intestinal failure patients have expanded the treatable patient population, directly increasing demand for GLP-2 analog therapies.

In addition, increasing clinical awareness of intestinal rehabilitation therapies and the proven ability of GLP-2 analogs to reduce dependence on total parenteral nutrition (TPN) are further fueling market growth. These therapies significantly improve patients' quality of life by enhancing intestinal absorption and decreasing long-term complications associated with TPN.

Market Restraints

Despite their clinical benefits, high treatment costs remain a major restraint for market growth. GLP-2 analog therapies involve complex manufacturing processes and substantial R&D investments. Moreover, these treatments often require daily or long-term administration, leading to a high annual financial burden on patients and healthcare systems. Cost constraints, especially in developing and price-sensitive regions, limit wider adoption and slow overall market expansion.

Market Opportunities

The market presents strong growth opportunities with the development of long-acting GLP-2 analogs. Pharmaceutical companies are increasingly focusing on weekly-dose formulations that improve patient compliance and reduce the inconvenience associated with daily injections. Pipeline candidates such as glepaglutide and apraglutide are designed to provide sustained therapeutic effects with reduced dosing frequency, which is expected to positively influence market growth.

Additionally, innovations in formulation stability and drug delivery technologies are expected to enhance therapeutic efficacy and expand future clinical applications of GLP-2 analogs.

Market Challenges

The GLP-2 analogs market faces challenges related to stringent regulatory requirements for biologic drugs. Regulatory authorities require extensive clinical trials to ensure long-term safety and efficacy, particularly due to concerns related to gastrointestinal adverse effects and other potential risks. These regulatory hurdles increase development costs, extend approval timelines, and may delay the commercialization of new pipeline products, thereby restraining market growth.

Market Trends

A major trend shaping the market is the shift from total parenteral nutrition to GLP-2-based drug therapies for managing short bowel syndrome. GLP-2 analogs offer a more targeted and physiological treatment approach by improving intestinal function and reducing reliance on invasive nutritional support.

Another important trend is the expansion of clinical indications beyond SBS. Ongoing research is evaluating the potential use of GLP-2 analogs in Crohn's disease, ulcerative colitis, chemotherapy-induced enteropathy, and steroid-refractory gastrointestinal graft-versus-host disease, which may broaden future market opportunities.

Segmentation Analysis

By drug type, the market is segmented into teduglutide and others. The teduglutide segment dominates the market due to its proven safety profile, established clinical efficacy, and regulatory approvals for SBS treatment. Other drugs, including long-acting investigational analogs, are expected to grow steadily during the forecast period.

Based on route of administration, the market is divided into parenteral and oral. The parenteral segment holds the largest share, as most approved GLP-2 analogs are injectable therapies used in intestinal failure patients. However, the oral segment is gaining traction due to higher patient compliance and advancements in oral peptide delivery systems.

By distribution channel, online and retail pharmacies account for a significant share due to improved accessibility and convenience, while hospital pharmacies continue to hold an important position owing to high inpatient treatment volumes.

Regional Outlook

North America led the global GLP-2 analogs market in 2025, with a market value of USD 1.23 billion, which increased to USD 1.43 billion in 2026. High adoption of advanced therapies, strong reimbursement frameworks, and robust R&D activities drive regional dominance. Europe holds a significant market share due to rising SBS prevalence and high healthcare spending. The Asia Pacific region is expected to witness substantial growth during the forecast period, supported by expanding clinical research and government initiatives for rare diseases. Latin America and the Middle East & Africa are anticipated to grow steadily, driven by rising awareness and improving access to advanced treatments.

Competitive Landscape

The GLP-2 analogs market is moderately concentrated, with key players such as Takeda Pharmaceutical Company Limited, Zealand Pharma, and Hanmi Pharm Co., Ltd. holding significant market shares. Takeda's strong position is supported by its approved GLP-2 analog teduglutide, extensive global presence, and high R&D investment. Other companies, including Ironwood, Entera Bio, OxThera, and Merck KGaA, are actively advancing pipeline products and expanding clinical research to strengthen their competitive positioning in the global market.

Conclusion

The GLP-2 analogs market is positioned for sustained growth, driven by the rising prevalence of short bowel syndrome (SBS) and increasing clinical adoption of targeted intestinal rehabilitation therapies. Valued at USD 1.20 billion in 2025, the market is projected to expand to USD 1.83 billion in 2026 and further reach USD 2.65 billion by 2034, growing at a CAGR of 6.08% during 2026-2034. The strong dominance of North America, supported by advanced healthcare infrastructure, high treatment adoption, and robust R&D activity, continues to shape the global market landscape.

While high treatment costs and stringent regulatory requirements remain key challenges, ongoing innovation-particularly the development of long-acting GLP-2 analogs and expansion into new clinical indications-offers meaningful growth potential. Established therapies such as teduglutide continue to anchor market demand, while pipeline candidates are expected to enhance patient compliance and broaden therapeutic options. Overall, continued clinical research, regulatory progress, and expanding awareness of SBS management are expected to support steady market expansion through 2034.

Segmentation By Drug

  • Teduglutide
  • Others

By Route of Administration

  • Oral
  • Parenteral

By Distribution Channel

  • Hospital Pharmacies
  • Online & Retail Pharmacies

By Geography

  • North America (By Drug, Route of Administration, Distribution Channel, and Country/ Sub-region)
    • U.S.
    • Canada
  • Europe (By Drug, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Germany
    • U.K
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Drug, Route of Administration, Distribution Channel, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • South Korea
    • Rest of Asia Pacific
  • Latin America (By Drug, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Drug, Route of Administration, Distribution Channel, and Country/Sub-region)
    • GCC
    • South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Short Bowel Syndrome, By Key Countries, 2025
  • 4.2. Pipeline Analysis, By Key Players
  • 4.3. New Product Launches, By Key Players
  • 4.4. Key Industry Developments (Mergers, Acquisitions, and Partnerships, etc.)
  • 4.5. Regolatory and Reimbursement Scenario, By Key Countries/Region

5. Global GLP-2 Analogs Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Drug
    • 5.1.1. Teduglutide
    • 5.1.2. Others
  • 5.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.2.1. Oral
    • 5.2.2. Parenteral
  • 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.3.1. Hospital Pharmacies
    • 5.3.2. Online & Retail Pharmacies
  • 5.4. Market Analysis, Insights and Forecast - By Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Latin America
    • 5.4.5. Middle East & Africa

6. North America GLP-2 Analogs Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Drug
    • 6.1.1. Teduglutide
    • 6.1.2. Others
  • 6.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.2.1. Oral
    • 6.2.2. Parenteral
  • 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.3.1. Hospital Pharmacies
    • 6.3.2. Online & Retail Pharmacies
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe GLP-2 Analogs Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Drug
    • 7.1.1. Teduglutide
    • 7.1.2. Others
  • 7.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.2.1. Oral
    • 7.2.2. Parenteral
  • 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.3.1. Hospital Pharmacies
    • 7.3.2. Online & Retail Pharmacies
  • 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.4.1. U.K.
    • 7.4.2. Germany
    • 7.4.3. France
    • 7.4.4. Spain
    • 7.4.5. Italy
    • 7.4.6. Scandinavia
    • 7.4.7. Rest of Europe

8. Asia Pacific GLP-2 Analogs Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Drug
    • 8.1.1. Teduglutide
    • 8.1.2. Others
  • 8.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.2.1. Oral
    • 8.2.2. Parenteral
  • 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Online & Retail Pharmacies
  • 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.4.1. Japan
    • 8.4.2. China
    • 8.4.3. India
    • 8.4.4. Australia
    • 8.4.5. Southeast Asia
    • 8.4.6. Rest of Asia Pacific

9. Latin America GLP-2 Analogs Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Drug
    • 9.1.1. Teduglutide
    • 9.1.2. Others
  • 9.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.2.1. Oral
    • 9.2.2. Parenteral
  • 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.3.1. Hospital Pharmacies
    • 9.3.2. Online & Retail Pharmacies
  • 9.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 9.4.1. Brazil
    • 9.4.2. Mexico
    • 9.4.3. Rest of Latin America

10. Middle East & Africa GLP-2 Analogs Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Drug
    • 10.1.1. Teduglutide
    • 10.1.2. Others
  • 10.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.2.1. Oral
    • 10.2.2. Parenteral
  • 10.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.3.1. Hospital Pharmacies
    • 10.3.2. Online & Retail Pharmacies
  • 10.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 10.4.1. GCC
    • 10.4.2. South Africa
    • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Nestle
      • 11.2.1.1. Overview
      • 11.2.1.2. Products
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Takeda Pharmaceutical Company Limited
      • 11.2.2.1. Overview
      • 11.2.2.2. Products
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. OxThera
      • 11.2.3.1. Overview
      • 11.2.3.2. Products
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Zealand Pharma
      • 11.2.4.1. Overview
      • 11.2.4.2. Products
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Ironwood
      • 11.2.5.1. Overview
      • 11.2.5.2. Products
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Hanmi Pharm Co., Ltd.
      • 11.2.6.1. Overview
      • 11.2.6.2. Products
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. Jaguar Health
      • 11.2.7.1. Overview
      • 11.2.7.2. Products
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Merck KGaA
      • 11.2.8.1. Overview
      • 11.2.8.2. Products
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. EnteraBio Ltd.
      • 11.2.9.1. Overview
      • 11.2.9.2. Products
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global GLP-2 Analogs Market Revenue (USD billion) Forecast, by Drug, 2021-2034
  • Table 2: Global GLP-2 Analogs Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 3: Global GLP-2 Analogs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 4: Global GLP-2 Analogs Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 5: North America GLP-2 Analogs Market Revenue (USD billion) Forecast, by Drug, 2021-2034
  • Table 6: North America GLP-2 Analogs Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 7: North America GLP-2 Analogs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 8: North America GLP-2 Analogs Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 9: Europe GLP-2 Analogs Market Revenue (USD billion) Forecast, by Drug, 2021-2034
  • Table 10: Europe GLP-2 Analogs Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 11: Europe GLP-2 Analogs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 12: Europe GLP-2 Analogs Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 13: Asia Pacific GLP-2 Analogs Market Revenue (USD billion) Forecast, by Drug, 2021-2034
  • Table 14: Asia Pacific GLP-2 Analogs Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 15: Asia Pacific GLP-2 Analogs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 16: Asia Pacific GLP-2 Analogs Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 17: Latin America GLP-2 Analogs Market Revenue (USD billion) Forecast, by Drug, 2021-2034
  • Table 18: Latin America GLP-2 Analogs Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 19: Latin America GLP-2 Analogs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 20: Latin America GLP-2 Analogs Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: Middle East & Africa GLP-2 Analogs Market Revenue (USD billion) Forecast, by Drug, 2021-2034
  • Table 22: Middle East & Africa GLP-2 Analogs Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 23: Middle East & Africa GLP-2 Analogs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 24: Middle East & Africa GLP-2 Analogs Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global GLP-2 Analogs Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global GLP-2 Analogs Market Value Share (%), by Drug, 2025 & 2034
  • Figure 3: Global GLP-2 Analogs Market Value Share (%), by Route of Administration, 2025 & 2034
  • Figure 4: Global GLP-2 Analogs Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 5: Global GLP-2 Analogs Market Value Share (%), by Region, 2025 & 2034
  • Figure 6: North America GLP-2 Analogs Market Value (USD billion), by Drug, 2025 & 2034
  • Figure 7: North America GLP-2 Analogs Market Value Share (%), by Drug, 2025
  • Figure 8: North America GLP-2 Analogs Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 9: North America GLP-2 Analogs Market Value Share (%), by Route of Administration, 2025
  • Figure 10: North America GLP-2 Analogs Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 11: North America GLP-2 Analogs Market Value Share (%), by Distribution Channel, 2025
  • Figure 12: North America GLP-2 Analogs Market Value (USD billion), By Country, 2025 & 2034
  • Figure 13: North America GLP-2 Analogs Market Value Share (%), By Country, 2025
  • Figure 14: Europe GLP-2 Analogs Market Value (USD billion), by Drug, 2025 & 2034
  • Figure 15: Europe GLP-2 Analogs Market Value Share (%), by Drug, 2025
  • Figure 16: Europe GLP-2 Analogs Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 17: Europe GLP-2 Analogs Market Value Share (%), by Route of Administration, 2025
  • Figure 18: Europe GLP-2 Analogs Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 19: Europe GLP-2 Analogs Market Value Share (%), by Distribution Channel, 2025
  • Figure 20: Europe GLP-2 Analogs Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 21: Europe GLP-2 Analogs Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 22: Asia Pacific GLP-2 Analogs Market Value (USD billion), by Drug, 2025 & 2034
  • Figure 23: Asia Pacific GLP-2 Analogs Market Value Share (%), by Drug, 2025
  • Figure 24: Asia Pacific GLP-2 Analogs Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 25: Asia Pacific GLP-2 Analogs Market Value Share (%), by Route of Administration, 2025
  • Figure 26: Asia Pacific GLP-2 Analogs Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 27: Asia Pacific GLP-2 Analogs Market Value Share (%), by Distribution Channel, 2025
  • Figure 28: Asia Pacific GLP-2 Analogs Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 29: Asia Pacific GLP-2 Analogs Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 30: Latin America GLP-2 Analogs Market Value (USD billion), by Drug, 2025 & 2034
  • Figure 31: Latin America GLP-2 Analogs Market Value Share (%), by Drug, 2025
  • Figure 32: Latin America GLP-2 Analogs Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 33: Latin America GLP-2 Analogs Market Value Share (%), by Route of Administration, 2025
  • Figure 34: Latin America GLP-2 Analogs Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 35: Latin America GLP-2 Analogs Market Value Share (%), by Distribution Channel, 2025
  • Figure 36: Latin America GLP-2 Analogs Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 37: Latin America GLP-2 Analogs Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 38: Middle East & Africa GLP-2 Analogs Market Value (USD billion), by Drug, 2025 & 2034
  • Figure 39: Middle East & Africa GLP-2 Analogs Market Value Share (%), by Drug, 2025
  • Figure 40: Middle East & Africa GLP-2 Analogs Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 41: Middle East & Africa GLP-2 Analogs Market Value Share (%), by Route of Administration, 2025
  • Figure 42: Middle East & Africa GLP-2 Analogs Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 43: Middle East & Africa GLP-2 Analogs Market Value Share (%), by Distribution Channel, 2025
  • Figure 44: Middle East & Africa GLP-2 Analogs Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 45: Middle East & Africa GLP-2 Analogs Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 46: Global GLP-2 Analogs Market Share (%), By Company, 2025